Education
About Us
Working with TipRanks
Follow Us
Marker Therapeutics Inc (MRKR)
NASDAQ:MRKR
Total Valuation
Marker Therapeutics has a market cap or net worth of $12.29M. The enterprise value is $9.54M.
Market Cap$12.29M
Enterprise Value$9.54M
Share Statistics
Marker Therapeutics has 12,938,910 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,938,910
Owned by Insiders35.88%
Owned by Institutions21.13%
Financial Efficiency
Marker Therapeutics’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -60.19%.
Return on Equity (ROE)-0.58
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-60.19%
Return on Capital Employed (ROCE)-0.60
Revenue Per Employee1.32M
Profits Per Employee-2.15M
Employee Count5
Asset Turnover0.30
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Marker Therapeutics is ―. Marker Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value1.50
Price to FCF―
Price to Operating Cash Flow-1.49
PEG Ratio―
Income Statement
In the last 12 months, Marker Therapeutics had revenue of 6.59M and earned -10.73M in profits. Earnings per share was -1.19.
Revenue6.59M
Gross Profit-6.88M
Operating Income-11.12M
Pretax Income-10.68M
Net Income-10.73M
EBITDA-4.53M
Earnings Per Share (EPS)-1.19
Cash Flow
In the last 12 months, operating cash flow was -10.88M and capital expenditures 2.00, giving a free cash flow of -10.88M billion.
Operating Cash Flow-10.88M
Free Cash Flow-10.88M
Free Cash Flow per Share-0.84
Dividends & Yields
Marker Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.03
52-Week Price Change-63.46%
50-Day Moving Average1.22
200-Day Moving Average1.70
Relative Strength Index (RSI)42.19
Average Volume (3m)1.86M
Important Dates
Marker Therapeutics upcoming earnings date is Nov 6, 2025, TBA (Confirmed).
Last Earnings DateAug 18, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date―
Financial Position
Marker Therapeutics as a current ratio of 6.36, with Debt / Equity ratio of 0.00%
Current Ratio6.36
Quick Ratio6.36
Debt to Market Cap0.00
Net Debt to EBITDA4.24
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Marker Therapeutics has paid 49.95K in taxes.
Income Tax49.95K
Effective Tax Rate>-0.01
Enterprise Valuation
Marker Therapeutics EV to EBITDA ratio is -1.93, with an EV/FCF ratio of -0.80.
EV to Sales1.33
EV to EBITDA-1.93
EV to Free Cash Flow-0.80
EV to Operating Cash Flow-0.80
Balance Sheet
Marker Therapeutics has $10.46M in cash and marketable securities with $0.00 in debt, giving a net cash position of $10.46M billion.
Cash & Marketable Securities$10.46M
Total Debt$0.00
Net Cash$10.46M
Net Cash Per Share$0.81
Tangible Book Value Per Share$2.07
Margins
Gross margin is -74.81%, with operating margin of -168.68%, and net profit margin of -162.81%.
Gross Margin-74.81%
Operating Margin-168.68%
Pretax Margin-162.05%
Net Profit Margin-162.81%
EBITDA Margin-68.68%
EBIT Margin-68.68%
Analyst Forecast
The average price target for Marker Therapeutics is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside742.11% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast44.55%
EPS Growth Forecast-17.92%